Literature DB >> 16371694

Ascertainment of meningococcal disease in Europe.

C Trotter1, S Samuelsson, A Perrocheau, S de Greeff, H de Melker, S Heuberger, M Ramsay.   

Abstract

Meningococcal disease surveillance in most countries is based upon a combination of statutory notification systems and laboratory reporting, both of which are recognised to underestimate the true burden of disease. The incidence of meningococcal disease varies throughout Europe, and although there are many reasons for this, it is important to quantify the degree of under-ascertainment in order to validate international comparisons. Here, we review the literature on the ascertainment of meningococcal disease in Europe and the available methods for estimating the degree of under-reporting. We found that the sensitivity of surveillance varies between countries and over time, with estimates ranging from 40% to 96%. We identified five methods suitable for conducting ascertainment studies, from simple comparative studies to more complicated capture-recapture and regression analyses. Studies of ascertainment may be used to identify weaknesses and biases in surveillance data, and facilitate the improvement of these systems. These findings are relevant to the surveillance of other infectious diseases, particularly those with lower mortality and a lower public profile than meningococcal disease, for which ascertainment may be worse.

Entities:  

Mesh:

Year:  2005        PMID: 16371694

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  11 in total

1.  Potential of recombinant opa proteins as vaccine candidates against hyperinvasive meningococci.

Authors:  M J Callaghan; S Lewis; M Sadarangani; S E S Bailey; H Chan; D J P Ferguson; J P Derrick; I Feavers; M C Maiden; A J Pollard
Journal:  Infect Immun       Date:  2011-04-04       Impact factor: 3.441

2.  Declining incidence of meningococcal disease in Denmark, confirmed by a capture-recapture analysis for 1994 and 2002.

Authors:  M F Howitz; S Samuelsson; K Mølbak
Journal:  Epidemiol Infect       Date:  2007-09-25       Impact factor: 2.451

3.  Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003-2005.

Authors:  S C de Greeff; H E de Melker; L M Schouls; L Spanjaard; M van Deuren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-21       Impact factor: 3.267

4.  Invasive meningococcal disease in children in Jerusalem.

Authors:  C Stein-Zamir; N Abramson; G Zentner; H Shoob; L Valinsky; C Block
Journal:  Epidemiol Infect       Date:  2007-07-30       Impact factor: 2.451

5.  Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.

Authors:  Chiara de Waure; Alessandro Miglietta; Darko Nedovic; Giovanna Mereu; Walter Ricciardi
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

6.  Opa protein repertoires of disease-causing and carried meningococci.

Authors:  Martin J Callaghan; Caroline Buckee; Noel D McCarthy; Ana Belén Ibarz Pavón; Keith A Jolley; Saul Faust; Stephen J Gray; Edward B Kaczmarski; Michael Levin; J Simon Kroll; Martin C J Maiden; Andrew J Pollard
Journal:  J Clin Microbiol       Date:  2008-05-28       Impact factor: 5.948

7.  Contribution of σ70 and σN Factors to Expression of Class II pilE in Neisseria meningitidis.

Authors:  Mariya Lobanovska; Christoph M Tang; Rachel M Exley
Journal:  J Bacteriol       Date:  2019-09-20       Impact factor: 3.490

8.  Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK.

Authors:  J Huels; K M Clements; L J McGARRY; G J Hill; J Wassil; S Kessabi
Journal:  Epidemiol Infect       Date:  2013-11-28       Impact factor: 4.434

9.  Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods.

Authors:  Cheryl L Gibbons; Marie-Josée J Mangen; Dietrich Plass; Arie H Havelaar; Russell John Brooke; Piotr Kramarz; Karen L Peterson; Anke L Stuurman; Alessandro Cassini; Eric M Fèvre; Mirjam E E Kretzschmar
Journal:  BMC Public Health       Date:  2014-02-11       Impact factor: 3.295

10.  Hospitalization rates and outcome of invasive bacterial vaccine-preventable diseases in Tuscany: a historical cohort study of the 2000-2016 period.

Authors:  Elena Chiappini; Federica Inturrisi; Elisa Orlandini; Maurizio de Martino; Chiara de Waure
Journal:  BMC Infect Dis       Date:  2018-08-13       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.